Intellectual Property - December 15, 2014
Japan Grants Patent to Nordic Nanovector
The Japan Patent Office (JPO) has issued patent no. 5646652 entitled “NOVEL RADIOIMMUNOCONJUGATES AND USES THEREOF” to Nordic Nanovector. The issued claims cover Nordic Nanovector’s proprietary radioimmunotherapy (RIT) technology, including the company`s lead product candidate Betalutin™, a new targeted agent for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL).
Collaboration - December 5, 2014
Nanovector, Affibody to Collaborate
Norway’s Nordic Nanovector ASA and Sweden’s Affibody AB announced that the companies have entered into a three-year collaborative research agreement to discover and develop new advanced radio-immunotherapies (RIT) for multiple myeloma. Backed by a Eurostars grant, the project will combine Affibody’s proprietary platforms with Nordic Nanovector’s radioimmunotherapy technology. The project aims to provide documentation necessary […]
Drug Development Pharma - June 12, 2014
Nordic Nanovector gets green light for Betalutin
The Norwegian company’s lead product candidate has been granted orphan designation in Europe. The European Medicines Agency (EMA) and the European Commission (EC) has now granted Betalutin orphan designation for treatment of follicular lymphoma in Europe. According to Nordic Nanovector, this will provide the company several advantages, The master travel anyone lisbon iowa singles stay […]
